How has been the historical performance of Balaxi Pharma?

Answer:The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years. Breakdown: Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023. The company's total assets increased to 310.34 Cr in March 2025 from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr in March 2025 from 258.34 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -35.00 Cr in March 2025 compared to 4.00 Cr in March 2024, while cash and cash equivalents decreased to 39.00 Cr in March 2025 from 62.00 Cr in March 2024.